Themis Medicare Issues Corrigendum for Preferential Warrants, Adjusts Terms
Themis Medicare Limited issued a corrigendum for its preferential warrant issuance to VMIPL. The Warrants Issue Price is revised to ₹102.87 (premium ₹101.87), increasing the total issue size to ₹47.28 crore. Initial payment is 25% (₹11.82 crore), with the balance due upon exercise. The corrigendum clarifies terms and compliance details.
The adjustment in the preferential issue price and total issue size, along with clarifications on payment terms, has a moderate impact on the potential fundraising amount and the terms of the transaction. This affects existing shareholders' dilution expectations and the company's capital structure.
The announcement is a corrigendum to a previous notice regarding preferential warrants. While it adjusts financial terms, it does not introduce significantly new positive or negative developments. The changes are primarily for clarification and compliance with exchange requirements.
Themis Medicare Limited has issued a corrigendum to its Postal Ballot Notice dated February 25, 2026, concerning the issuance of convertible equity warrants on a preferential basis to Vividhmargi Investments Private Limited (VMIPL), a promoter group company. This corrigendum is in response to observations and requests for clarification from the National Stock Exchange of India Limited (NSE).
The key changes introduced by the corrigendum relate to the pricing and aggregate value of the warrants. The Warrants Issue Price has been revised from ₹100 to ₹102.87 per warrant, with a corresponding increase in the premium from ₹99 to ₹101.87. Consequently, the total issue size has been adjusted upwards from ₹45.96 crore to ₹47.28 crore.
Furthermore, the payment structure for the warrants has been clarified. The initial payment at the time of subscription and allotment of each warrant remains 25% of the Warrants Issue Price, but the amounts have been revised due to the price change. The initial payment is now ₹11.82 crore (25% of ₹47.28 crore), compared to the previously stated ₹11.49 crore. The remaining 75% payment, to be made at the time of exercise, is now ₹35.46 crore, up from ₹34.47 crore.
The corrigendum also updates specific clauses within the explanatory statement, including clarifications on the utilization of funds and ensuring compliance with relevant SEBI regulations. The reference fiscal year has been updated from FY 2024-2025 to FY 2025-26. The corrigendum will be published in The Indian Express and Financial Express on March 11, 2026, and will be available on the websites of the stock exchanges and the company. Shareholders are provided with a 48-hour window to submit comments and can modify their votes by emailing the scrutinizer before the e-voting concludes on March 27, 2026, at 5:00 p.m.
What to do with a filing like this
Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.